11:57 AM EST, 01/09/2025 (MT Newswires) -- PureTech Health ( PRTC ) said Thursday the US Food and Drug Administration has given fast track designation to LYT-200 to treat acute myeloid leukemia.

The label was designed to expedite the assessment of drugs for serious diseases with unmet medical need, the company said.

The regulator previously granted orphan drug designation to LYT-200 to treat acute myeloid leukemia, as well as a separate fast track designation to treat head and neck cancers, the company said.

Price: 17.55, Change: -0.76, Percent Change: -4.15